Shire and Santaris extend their strategic alliance to discover and develop
LNA-drugs in the rare genetic disease field
HOERSHOLM, Denmark and SAN DIEGO, Aug. 23, 2013
HOERSHOLM, Denmark and SAN DIEGO, Aug. 23, 2013 /PRNewswire/ -- Santaris
Pharma A/S, a clinical-stage biopharmaceutical company focused on the
discovery and development of RNA-targeted therapies, today announced that its
long term partner, Shire has extended the existing partnership in the rare
genetic disease space.
(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO )
Under the terms of the extended agreement, Shire will have the right to
nominate additional collaboration targets for drug discovery and development.
Santaris will receive an upfront payment and, consistent with the initial
agreement, is eligible for research support, pre-clinical, clinical and sales
milestones and royalties on each product emerging from the collaboration.
Henrik Stage, President & CEO at Santaris Pharma A/S stated: "Our
collaboration with Shire is very important to us so we are very pleased with
the decision to extend the agreement and allow for more drug discovery and
development programs. We believe the LNA drug platform offers a unique
opportunity to develop drugs against the rapidly expanding number of disease
targets in the rare genetic disorder space."
Albert Seymour, VP, Discovery Research, Shire, stated: "We are delighted with
our partnership with Santaris, whose expertise and capabilities in LNA
antisense therapy complement Shire's drug discovery and development strengths.
Our hope is that the partnership will eventually translate into novel drugs
that will help patients suffering from debilitating rare diseases lead better
About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combines the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver LNA-based drug candidates against
RNA targets, both mRNA and microRNA, for a range of diseases including
cardiometabolic disorders, infectious and inflammatory diseases, cancer and
rare genetic disorders. LNA is also sometimes referred to as BNA (Bicyclic or
Bridged Nucleic Acid). LNA-based drugs are a promising new class of
therapeutics that are enabling scientists to develop drug candidates to work
through previously inaccessible clinical pathways. The LNA Drug Platform
overcomes the limitations of earlier antisense and siRNA technologies to
deliver potent single-stranded LNA-based drug candidates across a multitude of
disease states. The unique combination of small size and very high affinity
allows this new class of drugs candidates to potently and specifically inhibit
RNA targets in many different tissues without the need for complex delivery
vehicles. The most important features of LNA-based drugs include excellent
specificity providing optimal targeting; increased affinity to targets
providing improved potency; and favorable pharmacokinetic and
tissue-penetrating properties that allow systemic delivery of these drugs
without complex and potentially troublesome delivery vehicles.
About Santaris Pharma A/S Santaris Pharma A/S is a privately held
clinical-stage biopharmaceutical company focused on the discovery and
development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug
Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine
the company's proprietary LNA chemistry with its highly specialized and
targeted drug development capabilities to rapidly deliver potent
single-stranded LNA-based drug candidates across a multitude of disease
states. The company's research and development activities focus on infectious
diseases and cardiometabolic disorders, while partnerships with major
pharmaceutical companies include a range of therapeutic areas including
cancer, cardiovascular disease, infectious and inflammatory diseases, and rare
genetic disorders. The company has strategic partnerships with RaNA
Therapeutics, Bristol-Myers Squibb, miRagen Therapeutics, Shire, Pfizer,
GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent
estate, the company holds exclusive worldwide rights to manufacture and sell
products that comprise LNA as active ingredient for studies performed with a
view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is
headquartered in Denmark with operations in the United States. Please visit
www.santaris.com for more information.
Santaris Pharma A/S® is a registered trademark of Santaris Pharma A/S.
Santaris™ and LNA-antimiR™ are trademarks of Santaris Pharma A/S.
Contact: Henrik Stage, President & CEO, Cell: +45 40260900, Company phone: +45
45 17 98 88, e-mail: email@example.com, www.santaris.com
Press spacebar to pause and continue. Press esc to stop.